Prevalence and Correlates of Prolonged Fatigue in a U.S. Sample of Adolescents
Publication: American Journal of Psychiatry
Abstract
Objective
Prolonged fatigue in adolescents has a major impact on social functioning and school attendance. In adults, prolonged fatigue substantially overlaps with mood and anxiety disorders. Extending the data to adolescents, the authors studied the prevalence and correlates of fatigue in a representative U.S. sample.
Method
The participants were 10,123 adolescents ages 13–18 years from the National Comorbidity Survey Adolescent Supplement. They were interviewed about prolonged fatigue, defined as extreme fatigue with at least one associated symptom (pains, dizziness, headache, sleep disturbance, inability to relax, irritability) that does not resolve by resting or relaxing and lasting at least 3 months.
Results
The prevalence of prolonged fatigue was 3.0% (SE=0.3), with 1.4% (SE=0.2) for prolonged fatigue only and 1.6% (SE=0.2) for prolonged fatigue concomitant with a depressive or anxiety disorder. Nearly 60% of the adolescents with prolonged fatigue only had severe or very severe disability, and their rates of poor physical and mental health were comparable to those of adolescents with mood or anxiety disorders only. Adolescents with prolonged fatigue and comorbid mood or anxiety disorders had significantly greater disability, poorer mental health, and more health service use than those with either condition alone.
Conclusions
These findings suggest that prolonged fatigue is associated with disability and is an important clinical entity independent of mood and anxiety disorders in adolescents. Persistent fatigue with a comorbid mood or anxiety state is related to even more functional impairment, suggesting that prolonged fatigue may reflect greater severity of mood and anxiety disorders in adolescents.
Prolonged fatigue states—unexplained fatigue lasting more than 3 months—are among the most commonly reported forms of health-related morbidity. International studies of adults suggest that community prevalence rates of prolonged fatigue vary from 1.1% to 3.8% (1–4). The prevalence of prolonged fatigue in community samples of adolescents is highly variable, ranging from 0.7% to 7.4% (5–7), depending on the assessment methods and definitions used.
Although there are multiple common medical causes of fatigue (e.g., acute inflammatory conditions, anemia, thyroid deficiency, sleep apnea, end-organ failure, cancer therapy, chronic infection, and autoimmune disorders), a substantial proportion of chronic or prolonged fatigue remains unexplained. These states have primarily been studied in internal medicine and by relevant population health and research agencies, in response to the disabling symptom complexes presented by these individuals. The U.S. Centers for Disease Control and Prevention (CDC) has been at the forefront internationally of syndrome definitions and the enabling of specific research programs (8).
Despite the long, rich, and cross-cultural history of primary chronic or prolonged fatigue, its classification has been a struggle in modern psychiatric classification systems, in part because of the causal attributions of its precursor, “neurasthenia,” by its early proponents (9, 10) and its strong overlap with mood and anxiety states. Indeed, studies of community samples of adults reveal that 44%–75% of persons with prolonged fatigue report comorbid anxiety or depressive disorders (1, 3, 4). Whereas ICD includes a category for neurasthenia, DSM does not recognize prolonged fatigue as a distinct entity (1, 11). An important finding from analyses of international collaborative data sets from population-based studies, primary care, and secondary or specialist care settings is that a common symptom structure underlies prolonged fatigue states across cultures and health care settings (12).
There are limited data on the prevalence and correlates of fatigue states and their association with mood and anxiety disorders in general population samples of adolescents. Because prolonged fatigue may be a feature of mood or other mental disorders (13) and has a substantial impact on functioning and school attendance (14–17), quantifying the magnitude and correlates of prolonged fatigue in adolescents is of major public health importance. Recent data from a longitudinal twin study including 2,459 individuals ages 12–25 years indicate that fatigue states are common in both males and females, emerge in early adolescence (age 12 years), and are often comorbid with psychological distress (18). With an increasing emphasis in clinical and neurobiological research on delineating underlying components of major mental disorders, there is an important gap in our knowledge about the age at onset and persistence of fatigue states and the developmental links with comorbid anxiety and mood disorders. This is particularly important in community-based samples.
The specific aims of the current study were to evaluate 1) the prevalence and reported age at onset of prolonged fatigue in a nationally representative sample of U.S. adolescents, 2) the overlap of prolonged fatigue with depressive and anxiety disorders, and 3) the extent to which prolonged fatigue identifies a distinct subgroup of adolescents with specific correlates (sociodemographic variables, clinical characteristics, health indicators, service use) who are separate from adolescents with depressive and anxiety disorders only and from healthy adolescents.
Method
Sample
The National Comorbidity Survey Adolescent Supplement (19) is a nationally representative face-to-face survey of 10,123 adolescents ages 13 to 18 in the United States. Interviews were conducted between February 2001 and January 2004, and they used a modified version of the World Health Organization’s Composite International Diagnostic Interview, version 3.0 (CIDI). The CIDI is a fully structured interview administered by trained lay interviewers to generate DSM-IV diagnoses, and it includes a section on fatigue (20). A dual-frame sample was used, consisting of a household subsample (N=904) and a school subsample (N=9,217) (21, 22). Recruitment and consent procedures were approved by the human subjects committees of Harvard Medical School and the University of Michigan.
Measurement of Prolonged Fatigue
Prolonged fatigue was assessed in a separate CIDI module. Respondents were categorized as having prolonged fatigue if they met the ICD-10 criteria for neurasthenia: A) having experienced extreme tiredness, weakness, or exhaustion after minor physical or mental efforts (i.e., walking, shopping, reading, writing) lasting a few months or longer; B) having at least one of the following symptoms: feelings of muscular aches and pains, dizziness, tension headache, sleep disturbance, inability to relax, or irritability; C) not being able to recover from the symptoms mentioned in criterion A by resting or relaxing; and D) having these symptoms at least 3 months. Although the ICD-10 criteria for neurasthenia usually exclude persons with co-occurring mood disorders, generalized anxiety disorder, or panic disorder, we did not use these exclusion criteria, since a goal was to examine patterns of comorbidity of neurasthenia. Hence, the subgroup with comorbid disorders is most analogous to patients meeting current international definitions of more severe major mood disorders, which are characterized by both psychological distress and significant somatic symptoms. Therefore, the sample was categorized into four groups: 1) respondents with prolonged fatigue only, 2) those with prolonged fatigue plus a co-occurring depressive or anxiety disorder (i.e., major depressive disorder, dysthymia, bipolar disorder, generalized anxiety disorder, or panic disorder), 3) those with only a depressive or anxiety disorder, and 4) those without any lifetime fatigue, depression, or anxiety. Note that respondents with depression or anxiety who lacked somatic symptoms may have had less severe forms of these disorders.
Measurement of Correlates
Sociodemographic variables recorded were gender, age, ethnicity, and education. Clinical characteristics included age at onset of prolonged fatigue, ages at earliest onset of depressive and anxiety disorders, and lifetime comorbidity with other DSM-IV psychiatric disorders assessed in the CIDI (social phobia, agoraphobia, specific phobia, and substance use disorder). In addition to these diagnoses, we determined the prevalence of mania and hypomania and the comorbidity of depressive disorders (major depressive disorder, dysthymia, bipolar disorder), anxiety disorders (generalized anxiety disorder, panic disorder), and substance use (alcohol abuse or dependence or drug abuse or dependence) in selected groups. Severity of role impairment was assessed with the Sheehan Disability Scale (23) and measured as the maximum score on four domains (home, school/work, family, social).
Several health indicators were also included. Presence of somatic disorders was based on chronic conditions assessed in the U.S. National Health Interview Survey (24). Respondents were asked whether they had ever experienced each of the conditions in this checklist and, if so, whether they experienced them at any time in the past year. We included the following conditions: migraine and other headaches, arthritis, chronic back or neck problems, chronic pain, allergies (including hay fever), and asthma. Smoking was categorized as never, ever, and current smoking. Body mass index (BMI) z scores were calculated from self-reported weight and height according to the 2000 CDC growth charts for the United States and were categorized into underweight (<5th percentile), normal (5th to <85th percentile), overweight (85th to <95th percentile), and obese (95th or higher percentile). Further, weekend and weekday sleep duration and self-reported physical and mental health were assessed.
Service use was based on parent reports for a subset (N=6,483) of the participants; information was collected on treatment in the past year for emotional or behavioral problems. Variables were created to indicate whether a person had received any mental health care (outpatient mental health clinic, mental health professional, drug or alcohol clinic, admission to psychiatric hospital or other mental health facility), any health care (any mental health care, general medical care, or school medication [subset of school services]), and any care (any mental health care, general medical care, human services, complementary or alternative medicine, juvenile justice, or school services) during the past year.
Statistical Analyses
The prevalences in the four groups were calculated for the total sample as well as by sex, age group, and ethnicity. Correlates of the four groups were evaluated, and differences among the three groups of adolescents with disorders were evaluated by using chi-square tests and analyses of variance (ANOVAs). A proportional hazard model was used to test differences in median age at onset. This was done in SUDAAN 10 (RTI International, Research Triangle Park, N.C.); all other analyses were done in SAS 9.2 (SAS Institute, Cary, N.C.). All analyses corrected for the complex sampling design and were weighted to adjust for differential probabilities of selection, nonresponse, and poststratification.
Results
Prevalence
The weighted prevalence of all cases of prolonged fatigue was 3.0% (SE=0.3), with 1.4% of the subjects (SE=0.2) reporting prolonged fatigue only and 1.6% (SE=0.2) with prolonged fatigue plus a depressive or anxiety disorder (Table 1). The prevalence was markedly higher in girls, with a girl-to-boy ratio of 3.0:1 for prolonged fatigue only and 4.3:1 for prolonged fatigue with depression/anxiety, and was higher in older adolescents. Table 2 shows the lifetime prevalence of comorbid disorders among all adolescents with prolonged fatigue. Nearly half of the adolescents with prolonged fatigue had a major depressive episode, while mania and dysthymia were less common. Of the anxiety disorders, specific phobia was the most common comorbid disorder, followed by social phobia and separation anxiety. Approximately one-fourth of the adolescents with prolonged fatigue had substance use disorders.
| Neither Disorder | Prolonged Fatigue Onlya | Prolonged Fatigue Plus Depressive or Anxiety Disordera,b | Depressive or Anxiety Disorder Onlyb,c | Overall Chi-Square Test (p) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Prevalence | Weighted Prevalence | Weighted Prevalence | Weighted Prevalence | ||||||||||
| Demographic Group | N | % | SE | N | % | SE | N | % | SE | N | % | SE | |
| Total | 8,309 | 82.1 | 0.7 | 143 | 1.4 | 0.2 | 148 | 1.6 | 0.2 | 1,523 | 14.9 | 0.6 | — |
| Sex | <0.0001 | ||||||||||||
| Girls | 3,995 | 76.7 | 0.9 | 101 | 2.1 | 0.3 | 110 | 2.6 | 0.4 | 964 | 18.6 | 0.9 | |
| Boys | 4,314 | 87.3 | 1.0 | 42 | 0.7 | 0.2 | 38 | 0.6 | 0.2 | 559 | 11.4 | 0.9 | |
| Age (years) | <0.0001 | ||||||||||||
| 13 or 14 | 3,355 | 87.0 | 1.0 | 47 | 1.0 | 0.2 | 30 | 0.9 | 0.8 | 438 | 11.1 | 0.8 | |
| 15 or 16 | 3,161 | 80.7 | 0.8 | 60 | 1.6 | 0.3 | 68 | 1.8 | 0.4 | 608 | 15.8 | 0.8 | |
| 17 or 18 | 1,793 | 76.9 | 1.4 | 36 | 1.6 | 0.6 | 50 | 2.3 | 0.4 | 477 | 19.2 | 1.4 | |
| Ethnicity | <0.30 | ||||||||||||
| White | 4,658 | 82.0 | 0.9 | 91 | 1.6 | 0.2 | 82 | 1.7 | 0.3 | 803 | 14.8 | 0.8 | |
| Hispanic | 1,530 | 80.7 | 1.6 | 19 | 1.1 | 0.4 | 36 | 2.3 | 0.9 | 329 | 15.9 | 1.0 | |
| Black | 1,619 | 83.7 | 1.0 | 23 | 1.0 | 0.3 | 23 | 1.1 | 0.2 | 288 | 14.2 | 1.0 | |
| Other | 502 | 83.5 | 2.3 | 10 | 1.3 | 0.5 | 7 | 0.3 | 0.2 | 103 | 14.9 | 2.2 | |
a
Prolonged fatigue was defined as extreme fatigue with at least one associated symptom (pains, dizziness, headache, sleep disturbance, inability to relax, irritability) that does not resolve by resting or relaxing and lasting at least 3 months.
b
Depressive and anxiety disorders included lifetime DSM-IV diagnoses of major depressive disorder, dysthymia, bipolar disorder, generalized anxiety disorder, or panic disorder.
c
No lifetime prolonged fatigue.
| Lifetime Prevalence | ||
|---|---|---|
| Comorbid Disorder | % | SE |
| Mood disorders | ||
| Major depressive episode | 46.5 | 4.7 |
| Mania | 3.8 | 1.4 |
| Dysthymia | 14.3 | 3.6 |
| Anxiety disorders | ||
| Generalized anxiety disorder | 14.8 | 4.0 |
| Panic disorder | 8.9 | 1.9 |
| Social phobia | 23.3 | 4.1 |
| Agoraphobia | 5.2 | 1.6 |
| Specific phobia | 33.9 | 4.8 |
| Separation anxiety | 17.5 | 3.0 |
| Substance use disorder | 27.0 | 6.0 |
a
Prolonged fatigue was defined as extreme fatigue with at least one associated symptom (pains, dizziness, headache, sleep disturbance, inability to relax, irritability) that does not resolve by resting or relaxing and lasting at least 3 months.
Correlates
Table 3 presents the clinical and somatic health correlates of prolonged fatigue. As expected, the highest magnitude of psychiatric comorbidity and disability was found in the group with fatigue plus depression or anxiety. There was still considerable comorbidity and disability in the group with anxiety or depression only and the group with fatigue only, with the rates of comorbidity being slightly lower in the group with fatigue only (see also Figure 1). However, the only statistically significant differences between diagnostic groups emerged for disability and social phobia. The presence of both anxiety and depressive disorders was recorded for 26.7% (SE=6.0) of the comorbid fatigue group, compared with 14.7% (SE=1.4) of the group with only depression/anxiety (not tabulated). Mania and hypomania were present in 7.2% (SE=2.6) and 12.1% (3.6) of the adolescents in the comorbid fatigue group and in 6.0% (SE=0.7) and 9.8% (SE=1.1) of the persons in the group with only depression/anxiety, respectively (not tabulated). There were no differences in the median ages at onset of fatigue, depression, and anxiety across groups. With respect to physical health indicators, the group with fatigue only had the highest rates of somatic comorbidity overall, although the post hoc differences between diagnostic groups did not reach statistical significance. The adolescents with fatigue plus depression/anxiety were more likely to be current smokers and to have normal weight. Sleep duration on weekdays was marginally lower in both fatigue groups, but was marginally longer on weekend days, compared with the group with depression/anxiety only and the group with no disorders. Self-ratings of reported physical and mental health are shown in Table 4 and Figure 1. Ratings of physical and mental health were lowest for the adolescents with comorbid fatigue and depression/anxiety. For mental health, the differences between diagnostic groups were statistically significant.
| Variable | Neither Disorder (N=8,309) | Group 1: Prolonged Fatigue Only (N=143)a | Group 2: Prolonged Fatigue Plus Depressive or Anxiety Disorder (N=148)a,b | Group 3: Depressive or Anxiety Disorder Only (N=1,523)b,c | Overall Difference Among Groupsd | ||||
|---|---|---|---|---|---|---|---|---|---|
| Clinical characteristics | |||||||||
| Median | SE | Median | SE | Median | SE | Median | SE | p | |
| Age at onset (years) | |||||||||
| Fatigue | 13.1 | 0.3 | 12.8 | 0.3 | 0.69 | ||||
| Mood disorders | 12.2 | 0.5 | 11.7 | 0.1 | 0.51 | ||||
| Anxiety disorders | 11.8 | 0.6 | 11.1 | 0.3 | 0.70 | ||||
| % | SE | % | SE | % | SE | % | SE | p | |
| Disability (measured with Sheehan Disability Scale) | <0.001e,f | ||||||||
| None or mild | 10.2 | 3.5 | 0.8 | 0.9 | 13.9 | 2.1 | |||
| Moderate | 30.6 | 6.1 | 18.3 | 4.0 | 27.1 | 2.5 | |||
| Severe | 43.2 | 7.0 | 50.7 | 7.7 | 45.5 | 2.4 | |||
| Very severe | 16.0 | 6.6 | 30.2 | 7.2 | 13.4 | 2.0 | |||
| Comorbid mental disorders | |||||||||
| Social phobia | 3.3 | 0.3 | 11.5 | 3.4 | 33.5 | 6.7 | 14.4 | 1.3 | <0.0001e,g |
| Agoraphobia | 1.7 | 0.2 | 4.2 | 1.6 | 6.2 | 3.1 | 7.3 | 1.3 | <0.0001 |
| Specific phobia | 11.9 | 0.6 | 28.5 | 5.0 | 38.7 | 8.3 | 28.8 | 1.4 | <0.0001 |
| Separation anxiety | 5.0 | 0.3 | 17.6 | 4.1 | 17.5 | 3.6 | 14.7 | 1.1 | <0.0001 |
| Substance abuse or disorder | 8.6 | 0.6 | 16.2 | 5.0 | 36.4 | 7.9 | 25.6 | 1.8 | <0.0001 |
| Somatic health and behavioral indicators | |||||||||
| Somatic comorbidity | |||||||||
| Migraine | 4.7 | 0.3 | 13.1 | 2.8 | 9.2 | 2.6 | 11.0 | 1.1 | <0.0001 |
| Other headache | 18.7 | 0.1 | 37.6 | 6.0 | 39.7 | 6.9 | 30.3 | 1.7 | <0.0001 |
| Arthritis | 1.6 | 0.2 | 6.8 | 2.0 | 6.2 | 2.5 | 4.9 | 0.7 | <0.0001 |
| Chronic back or neck problems | 10.1 | 0.4 | 29.1 | 5.3 | 28.1 | 7.6 | 19.3 | 1.8 | <0.0001 |
| Chronic pain | 4.7 | 0.3 | 12.6 | 3.2 | 11.7 | 3.7 | 10.1 | 1.5 | <0.0001 |
| Allergies | 26.7 | 1.0 | 30.6 | 4.7 | 35.7 | 6.5 | 32.7 | 2.2 | 0.02 |
| Asthma | 15.3 | 0.5 | 26.0 | 3.8 | 19.9 | 5.6 | 20.0 | 1.6 | 0.02 |
| Smoking | <0.0001 | ||||||||
| Never | 89.1 | 0.9 | 81.1 | 4.7 | 65.1 | 8.0 | 74.0 | 2.4 | |
| Ever | 5.7 | 0.6 | 7.2 | 2.9 | 17.7 | 7.2 | 13.4 | 1.5 | |
| Current | 5.2 | 0.5 | 11.7 | 4.4 | 17.2 | 5.6 | 12.6 | 1.9 | |
| Weight category (percentile) | 0.55 | ||||||||
| Underweight (<5th) | 2.4 | 0.4 | 1.8 | 1.7 | 1.1 | 0.8 | 2.7 | 1.0 | |
| Normal (≥5th to <85th) | 68.3 | 0.9 | 72.3 | 5.1 | 76.6 | 4.1 | 65.3 | 2.2 | |
| Overweight (≥85th to <95th) | 15.4 | 0.7 | 13.1 | 3.9 | 13.7 | 3.1 | 15.5 | 1.6 | |
| Obese (≥95th) | 13.8 | 0.7 | 12.8 | 3.1 | 8.6 | 2.9 | 16.5 | 1.4 | |
| Mean | SE | Mean | SE | Mean | SE | Mean | SE | p | |
| Sleep duration (hours) | |||||||||
| Weekday | 7.8 | 0.03 | 7.2 | 0.1 | 7.1 | 0.2 | 7.4 | 0.1 | <0.0001 |
| Weekend day | 8.9 | 0.03 | 9.2 | 0.2 | 9.2 | 0.4 | 8.7 | 0.1 | 0.0002 |
a
Prolonged fatigue was defined as extreme fatigue with at least one associated symptom (pains, dizziness, headache, sleep disturbance, inability to relax, irritability) that does not resolve by resting or relaxing and lasting at least 3 months.
b
Depressive and anxiety disorders included lifetime DSM-IV diagnoses of major depressive disorder, dysthymia, bipolar disorder, generalized anxiety disorder, or panic disorder.
c
No lifetime prolonged fatigue.
d
Median ages at onset were compared by means of a proportional hazard model. Percentages were compared by means of chi-square analyses. Mean sleep durations were compared by analyses of variance.
e
Significant post hoc difference between groups 1 and 2 (p<0.05).
f
Significant post hoc difference between groups 2 and 3 (p<0.05).
g
Significant post hoc difference between groups 1 and 3 (p<0.05).
FIGURE 1. Disability, Health Perception, and Comorbidity of U.S. Adolescents With Prolonged Fatigue Only, Depression or Anxiety Only, Both, or Neithera
a Prolonged fatigue was defined as extreme fatigue with at least one associated symptom (pains, dizziness, headache, sleep disturbance, inability to relax, irritability) that does not resolve by resting or relaxing and lasting at least 3 months.
b Depressive and anxiety disorders included lifetime DSM-IV diagnoses of major depressive disorder, dysthymia, bipolar disorder, generalized anxiety disorder, or panic disorder.
c Measured only in adolescents with prolonged fatigue, depression, and/or an anxiety disorder.
| Neither Disorder (N=8,309) | Group 1: Prolonged Fatigue Only (N=143)a | Group 2: Prolonged Fatigue Plus Depressive or Anxiety Disorder (N=148)a,b | Group 3: Depressive or Anxiety Disorder Only (N=1,523)b,c | Overall Chi-Square Test (p) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Health Rating | % | SE | % | SE | % | SE | % | SE | |
| Physical health | <0.0001 | ||||||||
| Excellent | 17.8 | 0.8 | 13.3 | 4.2 | 7.1 | 2.3 | 10.9 | 1.6 | |
| Very good | 37.5 | 1.1 | 21.7 | 4.6 | 21.7 | 4.8 | 31.5 | 2.0 | |
| Good | 33.8 | 0.9 | 49.1 | 5.8 | 39.1 | 5.7 | 37.1 | 1.9 | |
| Fair | 10.1 | 0.5 | 15.2 | 5.7 | 28.2 | 6.7 | 17.5 | 1.3 | |
| Poor | 0.8 | 0.2 | 0.8 | 0.6 | 3.9 | 1.7 | 3.0 | 0.6 | |
| Mental health | <0.0001d,e | ||||||||
| Excellent | 28.8 | 0.8 | 22.0 | 7.5 | 5.4 | 1.8 | 13.9 | 1.6 | |
| Very good | 39.9 | 1.0 | 33.3 | 7.2 | 19.8 | 4.3 | 35.7 | 1.7 | |
| Good | 26.9 | 0.9 | 26.8 | 3.9 | 47.8 | 6.2 | 33.0 | 1.9 | |
| Fair | 4.6 | 0.4 | 17.7 | 3.9 | 20.6 | 4.9 | 15.9 | 1.1 | |
| Poor | 0.2 | 0.1 | 0.3 | 0.2 | 6.5 | 4.0 | 1.6 | 0.4 | |
a
Prolonged fatigue was defined as extreme fatigue with at least one associated symptom (pains, dizziness, headache, sleep disturbance, inability to relax, irritability) that does not resolve by resting or relaxing and lasting at least 3 months.
b
Depressive and anxiety disorders included lifetime DSM-IV diagnoses of major depressive disorder, dysthymia, bipolar disorder, generalized anxiety disorder, or panic disorder.
c
No lifetime prolonged fatigue.
d
Significant post hoc difference between groups 1 and 2 (p<0.05).
e
Significant post hoc difference between groups 2 and 3 (p<0.05).
As shown in Table 5, there were significant differences in the patterns of health and service use between the groups. Persons with fatigue only had low treatment rates, despite their considerable psychiatric comorbidity. In contrast, adolescents with fatigue plus depression or anxiety had an almost twofold higher service use rate than the adolescents with only depression or anxiety. Differences in general medical care, any health care, and any care were significantly different between groups, with the comorbid group having the highest treatment rates, followed by the depression/anxiety group, while the group with fatigue only had the lowest treatment rates among the groups with psychiatric disorders.
| Type of Service for Emotional or Behavioral Symptoms | Neither Disorder (N=5,315) | Group 1: Prolonged Fatigue Only (N=103)a | Group 2: Prolonged Fatigue Plus Depressive or Anxiety Disorder (N=90)a,b | Group 3: Depressive or Anxiety Disorder Only (N=975)b,c | Overall Chi-Square Test (p) | ||||
|---|---|---|---|---|---|---|---|---|---|
| % | SE | % | SE | % | SE | % | SE | ||
| Any mental health service | 6.7 | 0.6 | 7.7 | 4.8 | 31.8 | 13.7 | 16.5 | 2.2 | <0.0001 |
| General medical care | 3.0 | 0.3 | 3.3 | 1.7 | 21.7 | 8.8 | 7.9 | 1.6 | <0.0001d-f |
| Human services | 1.6 | 0.3 | 0.1 | 0.1 | 4.0 | 2.2 | 4.1 | 0.8 | <0.0001 |
| School services | 6.1 | 0.6 | 5.3 | 2.6 | 10.8 | 4.2 | 12.4 | 1.8 | <0.0001 |
| Any health care | 10.2 | 0.7 | 12.1 | 5.2 | 50.3 | 12.7 | 23.7 | 2.6 | <0.0001d-f |
| Any care | 15.2 | 1.0 | 13.7 | 5.3 | 60.0 | 10.5 | 32.3 | 2.9 | <0.0001d-f |
a
Prolonged fatigue was defined as extreme fatigue with at least one associated symptom (pains, dizziness, headache, sleep disturbance, inability to relax, irritability) that does not resolve by resting or relaxing and lasting at least 3 months.
b
Depressive and anxiety disorders included lifetime DSM-IV diagnoses of major depressive disorder, dysthymia, bipolar disorder, generalized anxiety disorder, or panic disorder.
c
No lifetime prolonged fatigue.
d
Significant post hoc difference between groups 1 and 2 (p<0.05).
eSignificant post hoc difference between groups 1 and 3 (p<0.05).
f
Significant post hoc difference between groups 2 and 3 (p<0.05).
Sex Differences
Although the small numbers of boys in the fatigue groups did not allow for stratified analyses, we describe here some notable differences between girls and boys (not tabulated). Among boys, anxiety onset was earlier in those with depression/anxiety only than in the comorbid fatigue and depression/anxiety group (median age, 9.9 versus 12.1), but such a difference was not observed in girls. Social phobia was more common in girls with fatigue and comorbid depression/anxiety than in boys in the same group (37.1% versus 19.6%), while boys with fatigue only had a higher rate of substance use than girls with fatigue only (35.2% versus 9.8%). In general, boys smoked more often than girls. The proportion of current smokers was 33.0% for boys with fatigue only, compared with 28.5% and 12.2% in the comorbid group and the group with depression/anxiety only, respectively. In girls, the percentages in these three groups were 4.6%, 14.3%, and 12.8%, respectively. In boys, the fatigue-only group had the shortest sleep duration on weekdays, while in girls, the group with fatigue plus depression/anxiety had the shortest sleep duration on weekdays. With respect to self-rated health across the three groups, girls were more likely than boys to rate their health as fair or poor. The largest sex differences were observed for service use. Boys with fatigue plus comorbid depression/anxiety were less likely to receive any mental health care or general medical care than girls in that same group (6.2% versus 38.5% for any mental health care, 12.5% versus 24.1% for general medical care). Boys in all three groups were more likely than girls to receive care from school services.
Discussion
This study begins to address the current gap in knowledge regarding the magnitude, age at onset, and correlates of prolonged fatigue and other major mood disorders in the U.S. adolescent population. Similar to the few previous studies of adolescents (5–7), this study reveals that persistent and disabling fatigue states are common, affecting about 3% of the adolescent population. Consistent with cases in prior adult studies (1, 3, 4), about one-half of the cases of prolonged fatigue are comorbid with anxiety or depressive disorders. However, youth with persistent fatigue without comorbid depression or anxiety also exhibited substantial impairment, suggesting that fatigue states are themselves an important clinical entity.
Adolescents with persistent fatigue without comorbid mood or anxiety disorders had a striking degree of disability, with about 60% reporting severe or very severe levels of disability across functional domains. It was also interesting that they lacked the common risk factors for poor health in adolescents, such as smoking and other substance use. Although depression is generally thought to be associated with higher BMI, the lower rate of obesity among those with fatigue plus depression or anxiety may indicate that fatigue could also characterize a distinct subgroup of adolescents with anxiety and depression. Similar to adolescents with depression or anxiety, those with prolonged fatigue had higher rates of pain-related conditions, including arthritis, back and neck pain, and headaches, than were found in adolescents without these disorders. This is consistent with the patterns of common somatic symptoms previously reported from a large sample of adolescent twins (18) and the finding in that study that the genetic and environmental determinants of those symptoms were somewhat separate from those associated with anxiety and depression alone.
These results demonstrate that the presence of fatigue in adolescents with anxiety or depression results in a clinical presentation with more comorbidity and more severity or disability than anxiety or depression without fatigue. This suggests that the presence of fatigue may be used in clinical practice as an indicator of a more severe depressive or anxiety disorder. As predicted by the general hypothesis that adolescents who have comorbid fatigue and mood disorders are most likely to represent subjects with more severe depressive disorders (25), we found that those with both conditions also had the highest rate of services use. Those with either prolonged fatigue only or anxiety/depression only used fewer services. While from the perspective of illness severity these differences may appear appropriate, they also highlight the extent to which young persons with disabling fatigue only or anxiety/depressive syndromes only do not receive care. If less severe forms are risk states for the onset of the more severe comorbid form, as would be predicted by other adolescent and adult studies of these overlapping phenotypes (18), then the opportunity for secondary prevention of that later morbidity is not being addressed.
A variety of other developmental, longitudinal, and genetically informed studies of prolonged fatigue states have demonstrated that comorbidity with other mental disorders is common, particularly major mood disorders (12, 18, 26–30). Previous studies support the notion that mood disorders and fatigue states are intrinsically linked (presumably at the neurobiological level) and their comorbid state indicates a more severe disorder than either alone. However, there has been far less emphasis on investigating the age at onset of each of these conditions and the ways in which either state may represent an earlier phenotype of the same disorder or an independent risk factor for the development of either the comorbid or alternative condition. The prevalence of prolonged fatigue tends to be stable across adolescence, whereas mood and anxiety disorders tend to exhibit a large increase in prevalence with progression through the adolescent period (increasing from 11.1% to 19.2% from age 13 to 18). This suggests the role of other etiologic factors and is again consistent with the notion that somatic states such as prolonged fatigue may be due, at least in part, to genetic and environmental determinants that differ from those for common forms of anxiety and depression (18, 29). For example, one specific environmental factor that may be directly associated with sleep problems in adolescents is the widespread use of electronic media (31).
Although this study has several strengths, including the use of a large nationally representative sample of U.S. adolescents, some limitations should be regarded when interpreting the results. First, the assessment of lifetime disorders is based on retrospective recall, which may be biased. Second, the cross-sectional nature of the study does not allow us to evaluate temporal or longitudinal associations of fatigue and depression/anxiety phenotypes with great reliability; prospective studies are needed in this respect. Third, service use variables were based on questions about service use for emotional or behavioral symptoms but not for somatic complaints, and they were based on parent reports, which were available for only a subset of the sample. Fourth, the definition of prolonged fatigue was based on the ICD-10 definition of neurasthenia, which requires a duration of 3 months or longer, and this deviates from the traditional concept of fatigue, which requires a minimum of 6 months. Other differences include a lower number of somatic symptoms in our definition than is required for chronic fatigue syndrome, which requires multiple physical symptoms that include pain in multiple joints, sore throat, and tender lymph nodes. However, the recent International Consensus Criteria for Myalgic Encephalomyelitis—as chronic fatigue syndrome is often called—has discarded the duration criterion because “no other disease criteria require that diagnoses be withheld until after the patient has suffered with the affliction for six months” (32). Accordingly, any significant fatigue state that causes considerable disability may warrant further medical and psychological assessment and, when present, certainly should be regarded as an indicator for severity when comorbid with depression or anxiety disorders.
In conclusion, this study demonstrates that prolonged fatigue is a disabling condition in U.S. adolescents and is often accompanied by substantial psychiatric comorbidity. Comorbid fatigue states may indicate greater severity of depressive and anxiety disorders in adolescents, and even in the absence of comorbidity, the substantial disability and comorbidity with somatic conditions, particularly pain conditions, among those with fatigue states alone also suggest that prolonged fatigue is a clinically relevant entity. The high magnitude of comorbidity with physical disorders also highlights the importance of fatigue states as an index of somatic conditions. Although there were relatively high rates of mental health service use among adolescents with comorbid fatigue and mood/anxiety disorders, there was a striking paucity of service use among those with either condition alone, despite high levels of disability.
Footnote
The views and opinions expressed in this article are those of the authors and should not be construed to represent the views of any of the sponsoring organizations or agencies or the U.S. government.
References
1.
Hickie I, Davenport T, Issakidis C, Andrews G: Neurasthenia: prevalence, disability and health care characteristics in the Australian community. Br J Psychiatry 2002; 181:56–61
2.
Fukuda K, Dobbins JG, Wilson LJ, Dunn RA, Wilcox K, Smallwood D: An epidemiologic study of fatigue with relevance for the chronic fatigue syndrome. J Psychiatr Res 1997; 31:19–29
3.
Gamma A, Angst J, Ajdacic V, Eich D, Rössler W: The spectra of neurasthenia and depression: course, stability and transitions. Eur Arch Psychiatry Clin Neurosci 2007; 257:120–127
4.
Merikangas K, Angst J: Neurasthenia in a longitudinal cohort study of young adults. Psychol Med 1994; 24:1013–1024
5.
Jones JF, Nisenbaum R, Solomon L, Reyes M, Reeves WC: Chronic fatigue syndrome and other fatiguing illnesses in adolescents: a population-based study. J Adolesc Health 2004; 35:34–40
6.
Rimes KA, Goodman R, Hotopf M, Wessely S, Meltzer H, Chalder T: Incidence, prognosis, and risk factors for fatigue and chronic fatigue syndrome in adolescents: a prospective community study. Pediatrics 2007; 119:e603–e609
7.
Watanabe N, Stewart R, Jenkins R, Bhugra DK, Furukawa TA: The epidemiology of chronic fatigue, physical illness, and symptoms of common mental disorders: a cross-sectional survey from the second British National Survey of Psychiatric Morbidity. J Psychosom Res 2008; 64:357–362
8.
Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A; International Chronic Fatigue Syndrome Study Group: The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121:953–959
9.
Beard G: Neurasthenia, or nervous exhaustion. Boston Med Surg J 1869; 80:217–221
10.
Freud S: On the grounds for detaching a particular syndrome from neurasthenia under the description “anxiety neurosis” (1895 [1894]), in Complete Psychological Works, standard ed, vol 3. London, Hogarth Press, 1962, pp 87–118
11.
Harvey SB, Wessely S, Kuh D, Hotopf M: The relationship between fatigue and psychiatric disorders: evidence for the concept of neurasthenia. J Psychosom Res 2009; 66:445–454
12.
Hickie I, Davenport T, Vernon SD, Nisenbaum R, Reeves WC, Hadzi-Pavlovic D, Lloyd A; International Chronic Fatigue Syndrome Study Group: Are chronic fatigue and chronic fatigue syndrome valid clinical entities across countries and health-care settings? Aust NZ J Psychiatry 2009; 43:25–35
13.
Addington AM, Gallo JJ, Ford DE, Eaton WW: Epidemiology of unexplained fatigue and major depression in the community: the Baltimore ECA follow-up, 1981–1994. Psychol Med 2001; 31:1037–1044
14.
Bakker RJ, van de Putte EM, Kuis W, Sinnema G: Risk factors for persistent fatigue with significant school absence in children and adolescents. Pediatrics 2009; 124:e89–e95
15.
Garralda ME, Rangel L: Impairment and coping in children and adolescents with chronic fatigue syndrome: a comparative study with other paediatric disorders. J Child Psychol Psychiatry 2004; 45:543–552
16.
Patel MX, Smith DG, Chalder T, Wessely S: Chronic fatigue syndrome in children: a cross sectional survey. Arch Dis Child 2003; 88:894–898
17.
van Geelen SM, Bakker RJ, Kuis W, van de Putte EM: Adolescent chronic fatigue syndrome: a follow-up study. Arch Pediatr Adolesc Med 2010; 164:810–814
18.
Hansell NK, Wright MJ, Medland SE, Davenport TA, Wray NR, Martin NG, Hickie IB: Genetic co-morbidity between neuroticism, anxiety/depression and somatic distress in a population sample of adolescent and young adult twins. Psychol Med 2012; 42:1249–1260
19.
Merikangas K, Avenevoli S, Costello J, Koretz D, Kessler RC: National Comorbidity Survey Replication Adolescent Supplement (NCS-A), I: background and measures. J Am Acad Child Adolesc Psychiatry 2009; 48:367–369
20.
Kessler RC, Ustün TB: The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004; 13:93–121
21.
Kessler RC, Avenevoli S, Costello EJ, Green JG, Gruber MJ, Heeringa S, Merikangas KR, Pennell BE, Sampson NA, Zaslavsky AM: National Comorbidity Survey Replication Adolescent Supplement (NCS-A), II: overview and design. J Am Acad Child Adolesc Psychiatry 2009; 48:380–385
22.
Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, Benjet C, Georgiades K, Swendsen J: Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication—Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010; 49:980–989
23.
Leon AC, Olfson M, Portera L, Farber L, Sheehan DV: Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997; 27:93–105
24.
Schoenborn CA, Adams PF, Schiller JS: Summary health statistics for the US population: National Health Interview Survey, 2000. Vital Health Stat 10 2003; issue 214 (November), pp 1–83
25.
Hickie IB, Davenport TA, Hadzi-Pavlovic D, Koschera A, Naismith SL, Scott EM, Wilhelm KA: Development of a simple screening tool for common mental disorders in general practice. Med J Aust 2001; 175(2 suppl):S10–S17
26.
van der Linden G, Chalder T, Hickie I, Koschera A, Sham P, Wessely S: Fatigue and psychiatric disorder: different or the same? Psychol Med 1999; 29:863–868
27.
Wilson A, Hickie I, Lloyd A, Hadzi-Pavlovic D, Boughton C, Dwyer J, Wakefield D: Longitudinal study of outcome of chronic fatigue syndrome. BMJ 1994; 308:756–759
28.
Hickie I, Lloyd A, Hadzi-Pavlovic D, Parker G, Bird K, Wakefield D: Can the chronic fatigue syndrome be defined by distinct clinical features? Psychol Med 1995; 25:925–935
29.
Hickie I, Bennett B, Lloyd A, Heath A, Martin N: Complex genetic and environmental relationships between psychological distress, fatigue and immune functioning: a twin study. Psychol Med 1999; 29:269–277
30.
Hickie I, Kirk K, Martin N: Unique genetic and environmental determinants of prolonged fatigue: a twin study. Psychol Med 1999; 29:259–268
31.
Cain N, Gradisar M: Electronic media use and sleep in school-aged children and adolescents: a review. Sleep Med 2010; 11:735–742
32.
Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles AC, Speight N, Vallings R, Bateman L, Baumgarten-Austrheim B, Bell DS, Carlo-Stella N, Chia J, Darragh A, Jo D, Lewis D, Light AR, Marshall-Gradisbik S, Mena I, Mikovits JA, Miwa K, Murovska M, Pall ML, Stevens S: Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med 2011; 270:327–338
Information & Authors
Information
Published In
History
Received: 6 April 2012
Revision received: 21 September 2012
Revision received: 27 November 2012
Accepted: 4 December 2012
Published online: 1 May 2013
Published in print: May 2013
Authors
Funding Information
Dr. Hickie reports that 1) he currently serves on the board of the Psychosis Australia Trust (unpaid position) and on the Defence Mental Health Advisory Group (government committee); 2) he currently receives fees for consulting or reports from Bupa Australia (private health insurance) as a member of the Medical Advisory Panel; 3) he has received travel support in the last 5 years from Servier, AstraZeneca, PricewaterhouseCoopers, the American Psychiatric Association, Returned and Services League (RSL) National Congress, the Chinese Society of Psychiatry and Neurology, Australian General Practice Network, and Focus—Sunshine Coast; 4) he has received research support in the last 5 years from Servier and Pfizer; 5) he has received payments for educational seminars or resources in the last 5 years from Servier, AstraZeneca, Pfizer (Wyeth), Eli Lilly, Broadcast Psychiatry, Janssen Cilag, Merck Sharp and Dohme, Elixir Healthcare Education, the Australian Mental Health Leadership Program, Australian Independent Schools of New South Wales, Australian Doctor Education, and Intelligence Squared Australia; 6) he previously had a business interest in St. George Neuropsychiatry Pty. Ltd. (director); 7) he previously held positions at the Australian Department of Health and Ageing (sitting fee for the National Advisory Council on Mental Health), the Australian National Council on Drugs, and Headspace: the National Youth Mental Health Foundation (director on behalf of the University of Sydney, a member of the company); 8) he previously served on the following government advisory committees: Mental Health Expert Working Group (member), Access to Allied Psychological Services (member of expert advisory committee), National Advisory Council for Mental Health (member), and Common Approach to Assessment Referral and System Task Force co-convened by the Minister for Families, Housing, and Community Services (member); 9) he previously received payments for consulting, reports, or advisory work from Drinkwise Australia, Western Australia (Labor) Government, the Australian Department of Health and Ageing, Sydney Magazine, Sydney City Council, the Royal Australian and New Zealand College of Psychiatry, Wyeth, and Eli Lilly; 10) his partner Dr. Elizabeth Scott is Clinical Director of Headspace Camperdown and Cambebelltown and previously had a business interest in Pearl 100, a partnership (ABN 55 251 484 962) trading as The Clinical Centre and registered to S. Duncan and St. George Neuropsychiatry Pty. Ltd.; 11) mental health research conducted at the Brain & Mind Research Institute has been supported by Servier, Pfizer, the Heart Foundation, Beyond Blue, and the Bupa Foundation. The other authors report no financial relationships with commercial interests.Supported by NIMH Intramural Research Program grant Z01 MH-002808-08 and, through the National Comorbidity Survey Adolescent Supplement (NCS-A) and the larger program of related NCS surveys, NIMH grant U01 MH-60220. Dr. Lamers is supported by a Rubicon Fellowship from the Netherlands Organisation for Scientific Research (NWO) and by a Supplemental Intramural Research Training Award from the NIMH Genetic Epidemiology Research Branch.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).